The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | An insight into the biology of CHIP and CCUS and their role in hematological malignancies
Amir T. Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, shares some insights into the biology of clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). Dr Fathi highlights the role of these precursor conditions in the development of myeloid malignancies, and further comments on the importance of closely monitoring patients with CHIP and CCUS in case of disease progression. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Clinical trial support – Abbvie, Servier, BMS
Consulting – Abbvie, Servier, BMS, Genentech, PureTech, Ipsen, Forma, Kite, Celgene, Amgen, Novartis, Takeda, Astellas, Immunogen, Mablytics, EnClear, Orum
